CJC-1295 research has become a central topic in the study of the growth hormone axis. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). It exists in two forms: one with a Drug Affinity Complex (DAC) and one without. Understanding the difference between these two versions is essential for researchers designing accurate study protocols.
What Is CJC-1295?
CJC-1295 is a modified peptide based on the first 29 amino acids of natural GHRH. Structural substitutions protect it from rapid enzymatic breakdown. This gives the peptide a longer active window than native GHRH. In laboratory models, CJC-1295 stimulates the pituitary gland to release growth hormone in a pulsatile pattern. Researchers study it to understand how GHRH signalling influences the wider growth hormone axis.
CJC-1295 With DAC
The DAC version adds a molecule that binds to blood albumin. This binding dramatically extends the peptide’s half-life. Reported half-life in the literature stretches to roughly six to eight days. As a result, a single administration in a study model produces an elevated baseline of growth hormone and IGF-1 over an extended period. This sustained elevation is often called a “GH bleed.” Researchers select the DAC form when they want to observe long-duration signalling with infrequent administration.
CJC-1295 Without DAC
The version without DAC is frequently labelled Mod GRF (1-29). It carries the same core modifications but lacks the albumin-binding complex. Its half-life is much shorter, typically around 30 minutes. This produces a sharp, clean pulse of growth hormone that closely mirrors the body’s natural rhythm. Many research designs pair this form with a growth hormone secretagogue such as Ipamorelin to study synergistic pulses. The short window makes it easier to isolate discrete signalling events.
Key Differences for Researchers
The primary distinction is duration. The DAC form delivers prolonged, steady elevation. The non-DAC form delivers brief, sharp pulses. Study design usually drives the choice. Protocols examining sustained IGF-1 exposure favour the DAC version. Protocols modelling natural pulsatile release favour the non-DAC version. Frequency of administration also differs. DAC allows infrequent dosing in a model, while non-DAC generally requires more frequent administration to maintain signalling.
Handling and Storage in Research
Both forms arrive as a lyophilized powder. Researchers reconstitute them with bacteriostatic water before use. Reconstituted peptide should be refrigerated and protected from light. Lyophilized vials remain stable longer when frozen. Careful handling preserves peptide integrity and supports reproducible results across a study.
Why the GHRH Axis Matters
Growth hormone-releasing hormone sits upstream of many metabolic and recovery processes. When GHRH signalling rises, the pituitary releases growth hormone, which in turn drives IGF-1 production in the liver. Researchers study CJC-1295 because it offers a controllable way to probe this cascade. By comparing the DAC and non-DAC forms, scientists can separate the effects of sustained signalling from the effects of natural pulses. This distinction helps clarify how timing and duration shape downstream growth hormone activity in a model.
Conclusion
CJC-1295 research continues to clarify how GHRH analogues shape growth hormone release. The DAC and non-DAC forms serve different experimental goals, one favouring sustained elevation and the other favouring natural pulses. Selecting the correct form is a foundational step in any GH axis study.
All products sold at EhBuddy Peptides are for laboratory and scientific research purposes only and are not intended for human or veterinary administration. EhBuddy Peptides ships all orders from within Canada.
Furthermore, researchers can review the peer-reviewed studies behind CJC-1295 research through the literature indexed on PubMed. Every listing here supports laboratory use only, and orders ship from Canada.
